Steven Cohen’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.8M Buy
+356,923
New +$34.3M 0.04% 661
2026
Q1
– Sell
-662,351
Closed -$21.7M – 4474
2025
Q4
$21.7M Buy
+662,351
New +$17.3M 0.02% 833
2021
Q3
– Sell
-18,791
Closed -$3.27M – 1238
2021
Q2
$3.27M Sell
18,791
-41,209
-69% -$7.49M 0.01% 679
2021
Q1
$11.9M Sell
60,000
-56,822
-49% -$10.9M 0.06% 389
2020
Q4
$23M Buy
+116,822
New +$24.2M 0.11% 251
2018
Q4
– Sell
-10,625
Closed -$2.54M – 1192
2018
Q3
$2.54M Buy
+10,625
New +$2.48M 0.01% 726

Other funds holding SYRE

Steven Cohen's SYRE Position: Q3 2026 in Review

Steven Cohen opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 356,923 shares worth $31.8M. The stake represents 0.04% of the portfolio and ranks #661 among its holdings. This is a return to the name: Steven Cohen previously reported a position in SYRE as recently as Q4 2025.

Steven Cohen first reported a position in SYRE in Q3 2018 and has held it in 6 quarters since. 285 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Steven Cohen held 356,923 shares of Spyre Therapeutics worth $31.8M as of Q3 2026.
  • Spyre Therapeutics was a new Steven Cohen position in Q3 2026.
  • Spyre Therapeutics made up 0.04% of Steven Cohen's portfolio in Q3 2026, its #661 holding.
  • Steven Cohen first reported a position in Spyre Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • 285 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.